Obinutuzumab Treatment for ANCA-Associated Vasculitis: A 12-Patient Retrospective Study

Chen Ye authored a retrospective clinical study on figshare assessing the efficacy and safety of obinutuzumab for treating antineutrophil cytoplasmic antibody-associated vasculitis. The dataset includes clinical and pathological data from 12 consecutive patients who received their first obinutuzumab treatment between September 2022 and December 2024. The median follow-up duration after treatment was 17.5 months.

Use Cases

• Compare remission rates between induction and maintenance therapy groups based on patient outcomes described in the results.
• Analyze the timing and patterns of B-cell reconstitution based on the 9-12 month timeline mentioned.
• Correlate ANCA level changes with treatment duration and B-cell depletion status as described.
• Assess the incidence and types of severe adverse events associated with this treatment regimen.

Strengths

• Data covers a specific, recent time range from September 2022 to December 2024.
• Study reports concrete outcomes: 3 of 4 induction patients achieved sustained remission, and 0 of 8 maintenance patients relapsed.
• Provides specific follow-up metrics, including a median duration of 17.5 months and B-cell reconstitution timelines.

Limitations

• Row count is unknown, which may limit suitability assessment.
• Column-level documentation is absent; field semantics must be inferred after download.
• The dataset is very small, with only 12 patient records, limiting statistical power.

Provenance

Source

figshare

Collection Method

Retrospective study of 12 consecutive patients.

Time Range

September 2022 to December 2024

Freshness

Last updated 2026-05-13 05:50:18; freshness should be verified.